$Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM)$

Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM)

Saved in:

Bibliographic Details
Main Authors:	E. Burton, V. Honaker, D. Milton, I. Glitza, R. Amaria, S. Patel, A. Diab, M. Wong, J. McQuade, C. Chung, J. Wefel, J. Li, M. Davies, H. Tawbi
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001484
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet